Skip to search formSkip to main contentSkip to account menu

PF 03491390

Known as: PF-03491390, PF03491390 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

emricasan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury…
In a mouse model of alpha-Fas-induced acute liver injury, the orally-administered caspase inhibitor PF-03491390 (formerly named… 
2007
2007
PF-03491390 INHIBITS LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION VIA SUPPRESSION OF PRO-APOPTOTIC CASPASE-ACTIVA- TION.
2007
2007
PF 03491390 reduces aminotransferase activity in HCV
  • 2007
  • Corpus ID: 195122329
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)